Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2015; 14: 5-15
Эволюция лечения острого лимфобластного лейкоза у детей: эмпирические, биологические и организационные аспекты
https://doi.org/10.24287/1726-1708-2015-14-1-5-15Аннотация
Список литературы
1. Мукерджи Сиддхартха. Царь всех болезней. Биография рака. Пер. с англ. М.: АСТ; 2013.
2. Barnes E. Caring and curing: paediatric cancer services since 1960. Eur J Cancer Care (Engl). 2005; 14(4): 373-80.
3. Pinkel D. History and development of total therapy for acute lymphocytic leukemia. In: Murphy S.B., Gilbert J.R. eds. Leukemia research: advances in cell biology and treatment. New York: Elsevier Science Publishing; 1983: 189-201.
4. Aur R.J., Simone J., Hustu H.O., Walters T., Borella L., Pratt C. et al. Central nervous system therapy and combination chemotherapy in childhood lymphocytic leukemia. Blood. 1971; 37(3): 272-81.
5. Simone J.V., Aur R.J., Hustu H.O., Verzosa M., Pinkel D. Combined modality therapy of acute lymphocytic leukemia. Cancer. 1975; 35(1): 25-35.
6. Махонова Л.А. Современные методы лечения острого лейкоза у детей. Автореф. дисс.. канд. мед. наук. М.; 1963.
7. Кисляк Н.С. Острый лейкоз у детей. Автореф. дисс.. докт. мед. наук. М.; 1966.
8. Кошель И.В. Клинико-патологическая оценка ремиссии острого лейкоза у детей. Автореф. дисс.. докт. мед. наук. М.; 1971.
9. Махонова Л.А. Материалы к клинике и лечению (химиотерапия и иммунотерапия) острого лейкоза у детей. Автореф. дисс.. докт. мед. наук. М.; 1973.
10. Дрбоглав Т.К. Клинико-лабораторная и морфологическая характеристика нейролейкоза у детей. Автореф. дисс.. докт. мед. наук. Рига; 1974.
11. Моисеенко Е.И. Лечение и профилактика нейролейкоза у детей. Автореф. дисс.. канд. мед. наук. М.; 1977.
12. Курмашов В.И. Нейролейкоз у детей. Автореф. дисс.. докт. мед. наук. М.; 1981.
13. Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985; 12(2): 131-48.
14. Bleyer W.A. Central nervous system leukemia. Pediatr Clin North Am. 1988; 35(4): 789-814.
15. Riehm H., Gadner H., Henze G. et al. Acute lymphoblastic leukemia: treatment in three BFM studies (1970-1981). In: Murphy S.B., Gilbert J.R. eds. Leukemia research: advances in cell biology and treatment. New York: Elsevier Science Publishing; 1983: 251-63.
16. Langermann H.J., Henze G., Wulf M., Riehm H. Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application. Klin Padiatr. 1982; 194(4): 209-13.
17. Riehm H., Feickert H.J., Schrappe М., Henze G., Schellong G. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Transfus. 1987; 30: 139-46.
18. Reiter A., Schrappe М., Ludwig W.D., Hiddemann W., Sauter S., Henze G. et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994; 84(9): 3122-33.
19. Veerman A.J.P. Diagnosis, prophylaxis and treatment of central nervous system involvement in acute lymphoblastic leukemia. In: Pui C.-H. ed. Treatment of acute leukemias. New directions for clinical research. Totowa, New Jersey: Humana Press Inc.; 2003: 173-80.
20. Ленская Р.В. Цитологические критерии диагноза и прогноза острого лейкоза у детей. Автореф. дисс.. докт. мед. наук. М.; 1983.
21. Румянцев А.Г. Острый лимфобластный лейкоз у детей (клинико-иммуноцитологические параллели, состояние иммунитета, тактика лечения и реабилитации). Автореф. дисс.. докт. мед. наук. М.; 1983.
22. Mаякова С.А. Лечение и прогноз острого лимфобластного лейкоза у детей. Автореф. дисс.. докт. мед. наук. М.; 1986.
23. Miller D.R., Miller L.P. Acute lymphoblastic leukemia in children: an update of clinical, biological and therapeutic aspects. Crit Rev Oncol Hematol. 1990; 10(2): 131-64.
24. Riehm H., Gadner H., Jessenberger K., Odenwald E., Tariverdian G., Vortisch M., Stuck B. Radikale kombinierte Chemo- und Radiotherapie der akuten Leukämie des Kindes - erster Erfahrungsbericht. In: Gross R., van de Loo J. eds. Leukämie. Berlin, Heidelberg, New York: Springer; 1972: 545-51.
25. Riehm H., Gadner H., Henze G., Langermann H.-J., Odenwald E. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol. 1980; 2(4): 299-306.
26. Henze G., Langermann H.J., Ritter J., Schellong G., Riehm H. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report from the BFM study group. Haematol Blood Transfus. 1981; 26: 87-93.
27. Möricke A., Zimmermann М., Reiter A., Henze G., Schrauder A., Gadner H. et al. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010; 24(2): 265-84.
28. Sullivan М.P., Chen Т., Dyment P.G., Hvizdala E., Steuber C.P. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group study. Blood. 1982; 60(4): 948-58.
29. Bleyer W.A., Coccia P.F., Sather H.N., Level C., Lukens J., Niebrugge D.J. et al. Reduction of central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol. 1983; 1(5): 317-25.
30. Meadows AT, Baum E, Fossati-Bellani F, Green D, Jenkin RD, Marsden B, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Ocol. 1985; 3(4): 532-8.
31. Румянцев А.Г., Самочатова Е.В., Хамдан Т. Терапия острого лимфобластного лейкоза у детей по программе BFM. Педиатрия. Журнал им. Г.Н. Сперанского. 1991; 70(11): 58-63.
32. Алейникова О.В. Современные технологии диагностики и лечения острых лейкозов у детей. Автореф. дисс.. докт. мед. наук. М.; 1999.
33. Карачунский А.И. Современная стратегия терапии ОЛЛ у детей. Автореф. дисс.. докт. мед. наук. М.; 1999.
34. Мякова Н.В. Эффективность терапии и прогностические факторы в мультицентровом исследовании протокола 0ЛЛ-БФМ-90М у детей с острым лимфобластным лейкозом. Автореф. дисс.. докт. мед. наук. М.; 2002.
35. Карачунский А.И., Румянцев А.Г, Штакельберг А., Самочатова Е.В., Байдун Л.В., Хартманн Р. Сравнение протоколов ALL-BFM-90 и ALL-MB-91 для лечения острого лимфобластного лейкоза у детей (предварительные результаты). Педиатрия. Журнал им. Г.Н. Сперанского. 1995; 74(2): 10-6.
36. Карачунский А.И., Мякова Н.В., Румянцева Ю.В., Тимаков А.М., Махортых Т.Ж., Фечина Л.Г. и др. Результаты мультицентрового исследования лечения острого лимфобластного лейкоза у детей по программам ALL-MB 91/ALL-BFM 90m: анализ эффективности и токсичности. Терапевтический архив. 2007; 79(7): 19-26.
37. Karachunskiy A., Herold R., von Stackelberg A., Miakova N., Timakow A., Mahortih T. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia. 2008; 22(6): 1144-53.
38. Ryalls M.R., Pinkerton C.R., Meller S.T., Talbot D., McElwain T.J. High-dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1992; 20(2): 119-32.
39. Yetgin S., Gürgey A., Tuncer A.M., Cetin M., Ozbek N., Sayli T. et al. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization. Leuk Res. 1998; 22(6): 485-93.
40. Ahlke E., Nowak-Göttl U., Schulze-Westhoff P., Werber G., Börste H., Würthwein G. et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Hematol. 1997; 96(4): 675-81.
41. Румянцева Ю.В. Риск-адаптированная терапия острого лимфобластного лейкоза у детей и подростков в исследовании ALL-MB-2002. Автореф. дисс.. докт. мед. наук. М.; 2011.
42. Румянцева Ю.В., Карачунский А.И., Алейникова О.В., Фечина Л.Г., Шамардина А.В., Литвинов Д.В. и др. Эффективность протокола ALL-MB-2002 у детей с острым лимфобластным лейкозом. Терапевтический архив. 2010; 82(7): 11-20.
43. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. М.: Медпрактика-М; 2009.
44. Семочкин С.В. Оптимизация технологий лечения лимфопролиферативных заболеваний у подростков и лиц молодого возраста. Автореф. дисс.. докт. мед. наук. М.; 2007.
45. Meadows A.T., Baum E., Fossati-Bellani F., Green D., Jenkin R.D., Marsden B. et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Ocol. 1985; 3(4): 532-8.
46. Schrappe S., Camitta B., Pui C.H., Eden T., Gaynon P., Gustafsson G. et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000; 14(12): 2193-4.
47. Stanulla М., Cario G., Meissner B., Schrauder A., Möricke A., Riehm H. et al. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia-- a perspective from the BFM Study Group. Blood Cells Mol Dis. 2007; 39(2): 160-3.
48. Kamps W.A., van der Pal-de Bruin K.M., Veerman A.J., Fiocco M., Bierings M., Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010; 24(2): 309-19.
49. Mitchell C., Richards S., Harrison C.J., Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia. 2010; 24(2): 406-18.
50. Schmiegelow K., Forestier E., Hellebostad М., Heyman M., Kristinsson J., Söderhäll S. et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010; 24(2): 345-54.
51. Brenner T.L., Evans W.E. Rationale for high-dose methotrexate in childhood acute lymphoblastic leukemia. In: Pui CH, ed. Treatment of acute leukemias. New directions for clinical research. Totowa, New Jersey: Humana Press Inc.; 2003: 339-56.
52. Leblanc Т., Auclerc M.F., Landman-Parker J. et al. High-dose methotrexate (8 g/m2) is beneficial to children with standard-risk acute lymphoblastic leukemia treated with daunorubicin. A result from the FRALLE 93B randomized study. In: ASH, 42nd Annual Meeting, December 1-5, 2000; San Francisco, California, USA. Blood. 2000; 96(11): 466a.
53. Рогачева Е.Р. Оптимизация ЦНС-направленной терапии в программном лечении острого лимфобластного лейкоза у детей. Автореф. дисс.. докт. мед. наук. М.; 2007.
54. Karachunskiy A., Roumiantseva J., Lagoiko S., Bührer C., Tallen G., Aleinikova O. et al. Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002. Leukemia. 2015 Mar 9. doi: 10.1038/leu.2015.63.
Pediatric Hematology/Oncology and Immunopathology. 2015; 14: 5-15
Evolution of therapy for acute lymphoblastic leukemia in children: Empirical, biological, and organizational aspects
https://doi.org/10.24287/1726-1708-2015-14-1-5-15Abstract
References
1. Mukerdzhi Siddkhartkha. Tsar' vsekh boleznei. Biografiya raka. Per. s angl. M.: AST; 2013.
2. Barnes E. Caring and curing: paediatric cancer services since 1960. Eur J Cancer Care (Engl). 2005; 14(4): 373-80.
3. Pinkel D. History and development of total therapy for acute lymphocytic leukemia. In: Murphy S.B., Gilbert J.R. eds. Leukemia research: advances in cell biology and treatment. New York: Elsevier Science Publishing; 1983: 189-201.
4. Aur R.J., Simone J., Hustu H.O., Walters T., Borella L., Pratt C. et al. Central nervous system therapy and combination chemotherapy in childhood lymphocytic leukemia. Blood. 1971; 37(3): 272-81.
5. Simone J.V., Aur R.J., Hustu H.O., Verzosa M., Pinkel D. Combined modality therapy of acute lymphocytic leukemia. Cancer. 1975; 35(1): 25-35.
6. Makhonova L.A. Sovremennye metody lecheniya ostrogo leikoza u detei. Avtoref. diss.. kand. med. nauk. M.; 1963.
7. Kislyak N.S. Ostryi leikoz u detei. Avtoref. diss.. dokt. med. nauk. M.; 1966.
8. Koshel' I.V. Kliniko-patologicheskaya otsenka remissii ostrogo leikoza u detei. Avtoref. diss.. dokt. med. nauk. M.; 1971.
9. Makhonova L.A. Materialy k klinike i lecheniyu (khimioterapiya i immunoterapiya) ostrogo leikoza u detei. Avtoref. diss.. dokt. med. nauk. M.; 1973.
10. Drboglav T.K. Kliniko-laboratornaya i morfologicheskaya kharakteristika neiroleikoza u detei. Avtoref. diss.. dokt. med. nauk. Riga; 1974.
11. Moiseenko E.I. Lechenie i profilaktika neiroleikoza u detei. Avtoref. diss.. kand. med. nauk. M.; 1977.
12. Kurmashov V.I. Neiroleikoz u detei. Avtoref. diss.. dokt. med. nauk. M.; 1981.
13. Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985; 12(2): 131-48.
14. Bleyer W.A. Central nervous system leukemia. Pediatr Clin North Am. 1988; 35(4): 789-814.
15. Riehm H., Gadner H., Henze G. et al. Acute lymphoblastic leukemia: treatment in three BFM studies (1970-1981). In: Murphy S.B., Gilbert J.R. eds. Leukemia research: advances in cell biology and treatment. New York: Elsevier Science Publishing; 1983: 251-63.
16. Langermann H.J., Henze G., Wulf M., Riehm H. Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application. Klin Padiatr. 1982; 194(4): 209-13.
17. Riehm H., Feickert H.J., Schrappe M., Henze G., Schellong G. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Transfus. 1987; 30: 139-46.
18. Reiter A., Schrappe M., Ludwig W.D., Hiddemann W., Sauter S., Henze G. et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994; 84(9): 3122-33.
19. Veerman A.J.P. Diagnosis, prophylaxis and treatment of central nervous system involvement in acute lymphoblastic leukemia. In: Pui C.-H. ed. Treatment of acute leukemias. New directions for clinical research. Totowa, New Jersey: Humana Press Inc.; 2003: 173-80.
20. Lenskaya R.V. Tsitologicheskie kriterii diagnoza i prognoza ostrogo leikoza u detei. Avtoref. diss.. dokt. med. nauk. M.; 1983.
21. Rumyantsev A.G. Ostryi limfoblastnyi leikoz u detei (kliniko-immunotsitologicheskie paralleli, sostoyanie immuniteta, taktika lecheniya i reabilitatsii). Avtoref. diss.. dokt. med. nauk. M.; 1983.
22. Mayakova S.A. Lechenie i prognoz ostrogo limfoblastnogo leikoza u detei. Avtoref. diss.. dokt. med. nauk. M.; 1986.
23. Miller D.R., Miller L.P. Acute lymphoblastic leukemia in children: an update of clinical, biological and therapeutic aspects. Crit Rev Oncol Hematol. 1990; 10(2): 131-64.
24. Riehm H., Gadner H., Jessenberger K., Odenwald E., Tariverdian G., Vortisch M., Stuck B. Radikale kombinierte Chemo- und Radiotherapie der akuten Leukämie des Kindes - erster Erfahrungsbericht. In: Gross R., van de Loo J. eds. Leukämie. Berlin, Heidelberg, New York: Springer; 1972: 545-51.
25. Riehm H., Gadner H., Henze G., Langermann H.-J., Odenwald E. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol. 1980; 2(4): 299-306.
26. Henze G., Langermann H.J., Ritter J., Schellong G., Riehm H. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report from the BFM study group. Haematol Blood Transfus. 1981; 26: 87-93.
27. Möricke A., Zimmermann M., Reiter A., Henze G., Schrauder A., Gadner H. et al. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010; 24(2): 265-84.
28. Sullivan M.P., Chen T., Dyment P.G., Hvizdala E., Steuber C.P. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group study. Blood. 1982; 60(4): 948-58.
29. Bleyer W.A., Coccia P.F., Sather H.N., Level C., Lukens J., Niebrugge D.J. et al. Reduction of central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol. 1983; 1(5): 317-25.
30. Meadows AT, Baum E, Fossati-Bellani F, Green D, Jenkin RD, Marsden B, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Ocol. 1985; 3(4): 532-8.
31. Rumyantsev A.G., Samochatova E.V., Khamdan T. Terapiya ostrogo limfoblastnogo leikoza u detei po programme BFM. Pediatriya. Zhurnal im. G.N. Speranskogo. 1991; 70(11): 58-63.
32. Aleinikova O.V. Sovremennye tekhnologii diagnostiki i lecheniya ostrykh leikozov u detei. Avtoref. diss.. dokt. med. nauk. M.; 1999.
33. Karachunskii A.I. Sovremennaya strategiya terapii OLL u detei. Avtoref. diss.. dokt. med. nauk. M.; 1999.
34. Myakova N.V. Effektivnost' terapii i prognosticheskie faktory v mul'titsentrovom issledovanii protokola 0LL-BFM-90M u detei s ostrym limfoblastnym leikozom. Avtoref. diss.. dokt. med. nauk. M.; 2002.
35. Karachunskii A.I., Rumyantsev A.G, Shtakel'berg A., Samochatova E.V., Baidun L.V., Khartmann R. Sravnenie protokolov ALL-BFM-90 i ALL-MB-91 dlya lecheniya ostrogo limfoblastnogo leikoza u detei (predvaritel'nye rezul'taty). Pediatriya. Zhurnal im. G.N. Speranskogo. 1995; 74(2): 10-6.
36. Karachunskii A.I., Myakova N.V., Rumyantseva Yu.V., Timakov A.M., Makhortykh T.Zh., Fechina L.G. i dr. Rezul'taty mul'titsentrovogo issledovaniya lecheniya ostrogo limfoblastnogo leikoza u detei po programmam ALL-MB 91/ALL-BFM 90m: analiz effektivnosti i toksichnosti. Terapevticheskii arkhiv. 2007; 79(7): 19-26.
37. Karachunskiy A., Herold R., von Stackelberg A., Miakova N., Timakow A., Mahortih T. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia. 2008; 22(6): 1144-53.
38. Ryalls M.R., Pinkerton C.R., Meller S.T., Talbot D., McElwain T.J. High-dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1992; 20(2): 119-32.
39. Yetgin S., Gürgey A., Tuncer A.M., Cetin M., Ozbek N., Sayli T. et al. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization. Leuk Res. 1998; 22(6): 485-93.
40. Ahlke E., Nowak-Göttl U., Schulze-Westhoff P., Werber G., Börste H., Würthwein G. et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Hematol. 1997; 96(4): 675-81.
41. Rumyantseva Yu.V. Risk-adaptirovannaya terapiya ostrogo limfoblastnogo leikoza u detei i podrostkov v issledovanii ALL-MB-2002. Avtoref. diss.. dokt. med. nauk. M.; 2011.
42. Rumyantseva Yu.V., Karachunskii A.I., Aleinikova O.V., Fechina L.G., Shamardina A.V., Litvinov D.V. i dr. Effektivnost' protokola ALL-MB-2002 u detei s ostrym limfoblastnym leikozom. Terapevticheskii arkhiv. 2010; 82(7): 11-20.
43. Rumyantsev A.G., Maschan A.A., Samochatova E.V. Soprovoditel'naya terapiya i kontrol' infektsii pri gematologicheskikh i onkologicheskikh zabolevaniyakh. M.: Medpraktika-M; 2009.
44. Semochkin S.V. Optimizatsiya tekhnologii lecheniya limfoproliferativnykh zabolevanii u podrostkov i lits molodogo vozrasta. Avtoref. diss.. dokt. med. nauk. M.; 2007.
45. Meadows A.T., Baum E., Fossati-Bellani F., Green D., Jenkin R.D., Marsden B. et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Ocol. 1985; 3(4): 532-8.
46. Schrappe S., Camitta B., Pui C.H., Eden T., Gaynon P., Gustafsson G. et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000; 14(12): 2193-4.
47. Stanulla M., Cario G., Meissner B., Schrauder A., Möricke A., Riehm H. et al. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia-- a perspective from the BFM Study Group. Blood Cells Mol Dis. 2007; 39(2): 160-3.
48. Kamps W.A., van der Pal-de Bruin K.M., Veerman A.J., Fiocco M., Bierings M., Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010; 24(2): 309-19.
49. Mitchell C., Richards S., Harrison C.J., Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia. 2010; 24(2): 406-18.
50. Schmiegelow K., Forestier E., Hellebostad M., Heyman M., Kristinsson J., Söderhäll S. et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010; 24(2): 345-54.
51. Brenner T.L., Evans W.E. Rationale for high-dose methotrexate in childhood acute lymphoblastic leukemia. In: Pui CH, ed. Treatment of acute leukemias. New directions for clinical research. Totowa, New Jersey: Humana Press Inc.; 2003: 339-56.
52. Leblanc T., Auclerc M.F., Landman-Parker J. et al. High-dose methotrexate (8 g/m2) is beneficial to children with standard-risk acute lymphoblastic leukemia treated with daunorubicin. A result from the FRALLE 93B randomized study. In: ASH, 42nd Annual Meeting, December 1-5, 2000; San Francisco, California, USA. Blood. 2000; 96(11): 466a.
53. Rogacheva E.R. Optimizatsiya TsNS-napravlennoi terapii v programmnom lechenii ostrogo limfoblastnogo leikoza u detei. Avtoref. diss.. dokt. med. nauk. M.; 2007.
54. Karachunskiy A., Roumiantseva J., Lagoiko S., Bührer C., Tallen G., Aleinikova O. et al. Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002. Leukemia. 2015 Mar 9. doi: 10.1038/leu.2015.63.
